Nautilus Biotechnology, Inc. (NAUT)
| Previous Close | 2.7600 |
| Open | 2.7300 |
| Bid | 2.6500 x 100 |
| Ask | 2.8000 x 100 |
| Day's Range | 2.6500 - 2.7900 |
| 52 Week Range | 2.2740 - 4.6500 |
| Volume | |
| Avg. Volume | 78,418 |
| Market Cap | 343.226M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
Simply Wall St.We're Hopeful That Nautilus Biotechnology (NASDAQ:NAUT) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GuruFocus.com
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
Explore key financial outcomes and strategic insights from Nautilus Biotechnology's first quarter of 2024, emphasizing growth in expenses and future expectations.
GlobeNewswireNautilus Biotechnology Reports First Quarter 2024 Financial Results
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. “We continued to make solid progress against our core development goals in Q1,” said Sujal Patel, CEO of Nautilus. “We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software
